ProCE Banner Activity

Clinical Pharmacokinetics of Subcutaneous Lenacapavir: Impact of Administration Sites

Conference Coverage
Slideset

In this phase I pharmacokinetic analysis, overlapping plasma exposures of lenacapavir were observed with injections in thigh, arm, or gluteus compared with abdomen, suggesting these may be acceptable alternative injection sites.

Released: October 23, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Janssen Therapeutics, Division of Janssen Products, LP., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare